April 2018 in “Journal of Investigative Dermatology” Fgf20 is important for the development and regulation of the cells that form the base of hair follicles.
95 citations,
November 2016 in “Journal of The American Academy of Dermatology” Treatments for permanent hair loss from scarring aim to stop further loss, not regrow hair, and vary by condition, with partial success common.
12 citations,
January 2021 in “Journal of Investigative Dermatology” Hair follicle studies suggest that maintaining telomere length could help treat hair loss and graying, but it's uncertain if mouse results apply to humans.
August 2023 in “Journal of Cosmetic Dermatology” QR678 Neo® improved seborrheic dermatitis symptoms in a small group of patients.
May 2004 in “Pediatric Dermatology” Atopic dermatitis may have genetic causes and can be treated with pharmacologic methods, glycerin creams, and controlling Staphylococcus aureus colonization.
7 citations,
April 2021 in “British Journal of Dermatology” Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
4 citations,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
1 citations,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
1 citations,
January 2023 in “SAGE open medical case reports” A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.
Different scalp and hair disorders are more common in certain ethnic groups, with the most common being androgenetic alopecia, which is treated with medications like minoxidil and finasteride.
2 citations,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
21 citations,
May 2017 in “Paediatric drugs” Individualized treatment plans are crucial for children with alopecia areata, with promising options like JAK inhibitors showing significant hair regrowth.
5 citations,
July 2020 in “Recent patents on inflammation & allergy drug discovery” Childhood Alopecia Areata causes hair loss and requires varied treatments, with psychological support being crucial.
September 1998 in “Journal of The European Academy of Dermatology and Venereology” Topical 5α-reductase inhibitor helps counteract hair loss and stabilize it.
32 citations,
June 2017 in “Journal of Pharmaceutical Sciences” Chitosan-coated nanoparticles improve skin delivery of hair loss treatments with fewer side effects.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.
July 2023 in “IntechOpen eBooks” New treatments for alopecia areata show promise, but more research is needed to confirm their effectiveness.
1 citations,
January 2019 in “Journal of the Egyptian Women's Dermatologic Society (Print)” Minoxidil 2% is more effective for female hair loss, but botanicals have fewer side effects.
August 2006 in “Experimental dermatology” New treatments targeting insulin, blood flow, and inflammation could improve hormone-related hair conditions with fewer side effects.
March 2018 in “Dermatología Argentina” The study found that the average age of women diagnosed with Frontal Fibrosing Alopecia in Argentina is higher than in other countries, but their symptoms are similar.
53 citations,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
2 citations,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
3 citations,
January 2010 in “Expert Opinion on Pharmacotherapy” No treatment fully stops excessive hair growth in women, but various methods can help manage it effectively.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
January 2024 in “Journal of Biosciences and Medicines” Future treatments for androgenic alopecia may focus on reactivating hair follicle stem cells and improving drug delivery.
29 citations,
April 2019 in “Lasers in Medical Science” Laser and minoxidil combo promotes better hair growth than minoxidil alone, safely.
15 citations,
January 2022 in “Immune Network/Immune network” New targeted immunotherapies are improving treatment for inflammatory skin diseases.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.